Amneal Pharmaceuticals, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
AMRX Nasdaq 2830 amneal.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Amneal Pharmaceuticals, Inc.

Amneal to Participate at Upcoming Investor Conferences - Dec 4th, 2024 1:00 pm
Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist - Nov 21st, 2024 9:05 pm
Amneal Pharmaceuticals Inc (AMRX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Nov 9th, 2024 9:01 pm
Amneal Reports Third Quarter 2024 Financial Results - Nov 8th, 2024 11:00 am
Amneal Pharmaceuticals (NASDAQ:AMRX) grows 3.0% this week, taking five-year gains to 211% - Oct 31st, 2024 2:42 pm
Amneal Receives U.S. FDA Approval of New Drug Application for Pyridostigmine Bromide Extended-Release Tablets - Oct 21st, 2024 12:00 pm
Amneal Pharmaceuticals Inc (AMRX) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Oct 9th, 2024 10:10 pm
Amneal to Report Third Quarter 2024 Results on November 8, 2024 - Oct 8th, 2024 8:05 pm
Amneal and Metsera Announce Strategic Collaboration to Develop and Supply Portfolio of Next-Generation Medicines for Obesity and Metabolic Diseases - Oct 1st, 2024 10:00 am
Amneal Launches CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules for Treatment of Parkinson’s Disease - Sep 23rd, 2024 12:00 pm
Amneal and Shilpa Announce U.S. FDA Approval of BORUZU™, the First Ready-to-Use Version of Bortezomib for subcutaneous administration - Sep 5th, 2024 8:05 pm
Amneal Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials - Aug 20th, 2024 3:26 pm
Insider Sale at Amneal Pharmaceuticals Inc (AMRX): Executive Vice President Nikita Shah Sells ... - Aug 17th, 2024 3:38 am
Amneal Pharmaceuticals Second Quarter 2024 Earnings: EPS: US$0.019 (vs US$0.078 in 2Q 2023) - Aug 11th, 2024 2:02 pm
Amneal Reports Second Quarter 2024 Financial Results - Aug 9th, 2024 10:05 am
Amneal Receives U.S. FDA Approval for IPX203 for Treatment of Parkinson’s Disease to Be Launched as CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules - Aug 7th, 2024 8:45 pm
Amneal Receives U.S. FDA Approval for Potassium Phosphates Injection IV Bags - Jul 29th, 2024 8:05 pm
In spite of recent selling, insiders still control 53% of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Jul 27th, 2024 1:48 pm
Amneal to Report Second Quarter 2024 Results on August 9, 2024 - Jul 11th, 2024 8:05 pm
Amneal Launches FOCINVEZ™, the First Ready-to-Use Version of Fosaprepitant - Jul 9th, 2024 8:05 pm